| Literature DB >> 29021702 |
Wei-Wei Dong1, Jinhua Zhao1, Fei-Liang Zhong1, Wen-Jing Zhu1, Jun Jiang1, Songquan Wu1, Deok-Chun Yang2, Donghao Li1, Lin-Hu Quan1.
Abstract
BACKGROUND: In general, after Panax ginseng is administered orally, intestinal microbes play a crucial role in its degradation and metabolization process. Studies on the metabolism of P. ginseng by microflora are important for obtaining a better understanding of their biological effects.Entities:
Keywords: LC–MS/MS; Panax ginseng; ginsenoside; metabolites; rat intestinal microflora
Year: 2017 PMID: 29021702 PMCID: PMC5628354 DOI: 10.1016/j.jgr.2016.11.002
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Fig. 1Chemical structures of protopanaxadiol (PPD)-type ginsenosides and protopanaxatriol (PPT)-type ginsenosides Glc β-D-glucopyranosyl, Arap α-L-arabinopyranosyl, Araf α-L-arabinofuranosyl, Xyl β-D-xylopyranosyl and Rha a-L-rhamnopyranosyl.
Fig. 2The typical total ion chromatogram of ginsenosides in the positive-ion mode by LC–MS/MS. (A) mixed standards; (B) Panax ginseng extract; (C) transformed P. ginseng extract by rat intestinal microflora within 24 h.
LC–MS/MS data in the positive-ion mode of standard ginsenosides.
| Ginsenoside | Rt (min) | Formula | Formula | ( | Product ions ( | Collision energy | |
|---|---|---|---|---|---|---|---|
| [M+Na]+ | [M-2H2O+H]+ | ||||||
| Rg1 | 15.8 | C42H72O14 | 800.0 | 823.4 | — | 643.6 [M-glc-H2O+Na]+ | 40 |
| Re | 15.8 | C48H82O18 | 946.0 | 969.5 | — | 789.2 [M-glc-H2O+Na]+ | 50 |
| Rf | 27.0 | C42H72O14 | 800.0 | 823.3 | — | 481.0 [M-(glc+glc)-H2O+Na]+ | 60 |
| Rb1 | 29.0 | C54H92O23 | 1108.0 | 1131.8 | — | 789.8 [M-(glc+glc)-H2O+Na]+ | 60 |
| Rc | 30.2 | C53H90O22 | 1078.0 | 1101.7 | — | 790.7 [M-(glc+ara)-H2O+Na]+ | 60 |
| Rb2 | 31.2 | C53H90O22 | 1078.0 | 1101.5 | — | 789.5 [M-(glc+ara)-H2O+Na]+ | 60 |
| Rd | 33.2 | C48H82O18 | 946.0 | 969.5 | — | 789.5 [M-glc-H2O+Na]+ | 50 |
| Rg2 | 30.8 | C42H72O13 | 784.0 | 807.5 | — | 481.0 [M-( rha+glc)-H2O+Na]+ | 56 |
| Rh1 | 31.4 | C36H62O9 | 638.0 | — | 603.0 | 423.3 [M-glc-H2O+H]+ | 10 |
| F1 | 33.9 | C36H58O9 | 638.0 | 661.4 | — | 481.2 [M-glc-H2O+Na]+ | 34 |
| F2 | 39.8 | C42H72O13 | 784.0 | 807.3 | — | 627.2 [M-glc-H2O+Na]+ | 40 |
| Rg3 | 41.6 | C42H72O13 | 784.0 | 807.5 | — | 465.0 [M-(glc+glc)-H2O+Na]+ | 67 |
| PPT | 44.5 | C30H52O4 | 476.0 | — | 441.0 | 423.3 [M-3H2O+H]+ | 10 |
| Compound K | 46.9 | C36H62O8 | 622.0 | 645.6 | — | 465.2 [M-glc-H2O+Na]+ | 30 |
| Rh2 | 47.5 | C36H62O8 | 622.0 | — | 587.0 | 407 [M-glc-H2O+H]+ | 10 |
Validation of the method for the LC–MS/MS determination of ginsenosides. LOD, limit of detection; LOQ, limit of quantitation; RSD, relative standard deviation
| Ginsenosides | Calibration curve equation | Correlation coefficient | Range | LOD | LOQ | Recovery % (RSD%) | ||
|---|---|---|---|---|---|---|---|---|
| 100 ng/mL | 1,000 ng/mL | 2,000 ng/mL | ||||||
| Re | y = 10.691x+ 2519.7 | R2 = 0.9973 | 50–5,000 | 7.51 | 24.99 | 104.4 (8.8) | 94.8 (6.6) | 116.5 (7.4) |
| Rg1 | y = 13.074x + 7896.7 | R2 = 0.9930 | 50–5,000 | 4.52 | 15.06 | 104.2 (11.1) | 116.8 (10.1) | 104.2 (8.9) |
| Rf | y = 9.7808x + 4535.2 | R2 = 0.9940 | 50–5,000 | 4.23 | 14.09 | 98.9 (8.9) | 98.2 (4.8) | 109.2 (9.4) |
| Rb1 | y = 4.7875x + 360.18 | R2 = 0.9964 | 50–5,000 | 12.01 | 40.03 | 97.6 (10.0) | 101.9 (0.6) | 106.2 (2.6) |
| Rc | y = 1.9243x + 520.16 | R2 = 0.9951 | 50–5,000 | 15.05 | 50.17 | 95.2 (7.3) | 95.1 (9.1) | 100.4 (4.5) |
| Rb2 | y = 1.6348x + 545.69 | R2 = 0.9955 | 50–5,000 | 12.04 | 40.12 | 90.4 (5.0) | 80.1 (8.8) | 109.1 (8.7) |
| Rd | y = 10.886x + 1745.9 | R2 = 0.9917 | 50–5,000 | 2.27 | 7.56 | 104.9 (6.9) | 101.7 (4.1) | 95.5 (3.9) |
| Rg2 | y = 0.5688x + 389.94 | R2 = 0.9902 | 50–5,000 | 20.05 | 66.83 | 115.8 (9.6) | 94.5 (10.7) | 111.7 (7.7) |
| Rh1 | y = 2.6693x + 170.07 | R2 = 0.9987 | 50–5,000 | 3.33 | 11.11 | 123.7 (9.5) | 107.7 (8.1) | 107.2 (2.2) |
| F1 | y = 4.189 x + 1495.3 | R2 = 0.9905 | 50–5,000 | 9.38 | 31.25 | 96.1 (8.1) | 100.5 (0.4) | 95.9 (4.9) |
| F2 | y = 11.384x + 4093.2 | R2 = 0.9910 | 50–5,000 | 2.64 | 8.79 | 104.9 (6.5) | 109.5 (11.5) | 107.2 (2.3) |
| Rg3 | y = 11.374x + 3971.8 | R2 = 0.9916 | 50–5,000 | 13.63 | 45.43 | 112.0 (9.2) | 99.2 (10.1) | 105.2 (7.6) |
| PPT | y = 5.7564x + 1116.6 | R2 = 0.9971 | 50–5,000 | 7.23 | 24.09 | 109.3 (4.8) | 86.5 (7.6) | 102.9 (0.9) |
| Compound K | y = 6.5315x + 1551.7 | R2 = 0.9953 | 50–5,000 | 5.35 | 17.83 | 78.5 (8.2) | 101.4 (9.6) | 82.5 (8.8) |
| Rh2 | y = 5.5618x + 1891.3 | R2 = 0.9978 | 50–5,000 | 4.68 | 13.59 | 82.0 (9.2) | 99.5 (8.7) | 113.7 (9.1) |
Fig. 3AThe representative multiple reaction monitoring (MRM) chromatograms of metabolites in the transformed (A) Panax ginseng sample and the (B) MS/MS fragmentation spectrum of the deglycosylated metabolites using electrospray ionization–MS/MS (ESI–MS/MS).
Fig. 4The (A) relative abundance and (B) concentration-time profiles of ginsenosides in the transformed Panax ginseng extract by rat intestinal microflora.
Fig. 5Proposed deglycosylated metabolic pathway of Panax ginseng saponins by rat intestinal microflora. (A) protopanaxadiol (PPD)-type ginsenosides metabolized by rat intestinal microflora; (B) protopanaxatriol (PPT)-type ginsenosides metabolized by rat intestinal microflora.